MetaCap

Wave Life Sciences Inc. (WVE)

NASDAQ: WVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.56-0.16 (-5.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

WVE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$504.91M
EPS (TTM)
-$1.07
52-week range
2.55 – 21.73
Day range
2.55 – 2.79
Volume / Avg
2.28M / 3.11M
Beta
—

52-week range

$2.55$21.73

WVE stock today

Shares of Wave Life Sciences (WVE) finished lower on Nov 20 at $2.56, a drop of 5.88% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, WVE sits near the bottom of its 52-week range of $2.55 to $21.73: 88.2% below the high, set on Dec 9, 2025 and 0.6% above the low. WVE is down 84.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.7%.

Wave Life Sciences has posted a net loss over the last twelve months (EPS of -$1.07), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Wave Life Sciences

Company profile

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Headquarters
Cambridge, MA
Employees
317
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Wave Life Sciences generated $42.7 million in revenue, down 60.5% from fiscal 2024, its first annual decline since 2024. Wave Life Sciences reported a net loss of $204.4 million, compared with a loss of $97.0 million a year earlier. Operating margin was -504.1%.

Wave Life Sciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$42.73M$108.30M$113.31M$3.65M$40.96M
Growth-60.55%-4.42%+3005.10%-91.09%+104.03%
Net income$-204.38M$-97.01M$-57.51M$-161.82M$-122.25M
EPS (diluted)$-1.21$-0.70$-0.54$-2.05$-2.36

Analyst forecast

Forecast

Consensus (21 analysts)

strong_buy

Avg. price target

$16.63+549.61%

  • Strong buy 2
  • Buy 17
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $44.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$-0.30 vs $-0.34
Surprise
+11.76%

WVE news

All WVE news

Wave Life Sciences peers

Health Care sector
WVE peer companies
CompanyPrice% ChgMarket capCompare
ALMSAlumis Inc.3.96-8.54%$514.09Mvs WVE
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs WVE
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs WVE
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs WVE
EVOEvotec SE ADR1.32-8.97%$469.11Mvs WVE
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs WVE
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs WVE
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs WVE

Indexes, lists and sector

Wave Life Sciences stock FAQ

What is Wave Life Sciences's stock price today?

WVE last traded at $2.56 as of Nov 20, 4:00 PM EST, down 5.88% on the day. Prices are delayed at least 15 minutes.

Who is Wave Life Sciences's CEO?

Dr. Paul B. Bolno M.B.A., M.D. is the chief executive officer of Wave Life Sciences Inc., which has about 317 employees.

What is the WVE 52-week high?

The 52-week high for WVE is $21.73 and the 52-week low is $2.55. The stock is currently 88.2% below its high.

Compare WVE